BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26248894)

  • 41. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
    Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
    J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
    Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
    Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
    Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.
    Mattison RJ; Luger SM; Lazarus HM
    Curr Opin Hematol; 2013 Mar; 20(2):93-9. PubMed ID: 23328452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
    Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia.
    Xubo G; Xingguo L; Xianguo W; Rongzhen X; Xibin X; Lin W; Lei Z; Xiaohong Z; Genbo X; Xiaoying Z
    Eur J Haematol; 2009 Oct; 83(4):292-301. PubMed ID: 19500135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
    Schultz KR; Massing B; Spinelli JJ; Gaynon PS; Wadsworth L
    Med Pediatr Oncol; 1997 Jul; 29(1):16-22. PubMed ID: 9142200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy.
    Ballo O; Stratmann J; Serve H; Steffen B; Finkelmeier F; Brandts C
    PLoS One; 2019; 14(9):e0223013. PubMed ID: 31568521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
    Li Y; Deng Z; Zho J; Ding B; Shi Y; Li Y
    Acta Haematol; 2014; 132(2):172-6. PubMed ID: 24603361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
    Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia.
    Archimbaud E; Treille-Ritouet D; Guyotat D; Viala JJ; Fiere D
    Leuk Res; 1987; 11(3):281-3. PubMed ID: 3470576
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
    Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
    Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemistry in Acute Myeloid Leukemia.
    Cruise MW
    Methods Mol Biol; 2017; 1633():33-49. PubMed ID: 28735479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of minimal residual disease in acute myeloid leukemia.
    Gerhartz HH; Schmetzer H
    Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Chen X; Othus M; Wood BL; Walter RB; Percival MM; Becker PS; Hendrie PC; Appelbaum FR; Estey EH
    Leuk Lymphoma; 2017 Nov; 58(11):2717-2719. PubMed ID: 28351184
    [No Abstract]   [Full Text] [Related]  

  • 57. Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia.
    Ngo N; Lampert IA; Naresh KN
    Br J Haematol; 2008 Feb; 140(3):279-86. PubMed ID: 17973948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Correlation with blast differentiation in bone marrow.
    Chang CC; Eshoa C; Kampalath B; Shidham VB; Perkins S
    Am J Clin Pathol; 2000 Nov; 114(5):807-11. PubMed ID: 11068557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
    Vial JP; Tabrizi R; Pigneux A; Lacombe F; Praloran V; Belloc F
    Cytometry B Clin Cytom; 2006 May; 70(3):115-23. PubMed ID: 16572429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.